| Targeting lysyl oxidase (LOX) overcomes chemotherapy resistance in triple negative breast cancer O Saatci, A Kaymak, U Raza, PG Ersan, O Akbulut, CE Banister, ... Nature communications 11 (1), 2416, 2020 | 209 | 2020 |
| The miR-644a/CTBP1/p53 axis suppresses drug resistance by simultaneous inhibition of cell survival and epithelial-mesenchymal transition in breast cancer U Raza, Ö Saatci, S Uhlmann, SA Ansari, E Eyüpoğlu, E Yurdusev, ... Oncotarget 7 (31), 49859, 2016 | 58 | 2016 |
| Reactivation of cAMP pathway by PDE4D inhibition represents a novel druggable axis for overcoming tamoxifen resistance in ER-positive breast cancer RR Mishra, N Belder, SA Ansari, M Kayhan, H Bal, U Raza, PG Ersan, ... Clinical Cancer Research 24 (8), 1987-2001, 2018 | 47 | 2018 |
| Thymidylate synthase maintains the de-differentiated state of triple negative breast cancers A Siddiqui, PN Gollavilli, A Schwab, ME Vazakidou, PG Ersan, ... Cell Death & Differentiation 26 (11), 2223-2236, 2019 | 36 | 2019 |
| Systems-level Analysis Reveals Multiple Modulators of Epithelial-mesenchymal Transition and Identifies DNAJB4 and CD81 as Novel Metastasis Inducers in Breast Cancer*[S] ZCU Kagiali, E Sanal, Ö Karayel, AN Polat, Ö Saatci, PG Ersan, K Trappe, ... Molecular & Cellular Proteomics 18 (9), 1756-1771, 2019 | 31 | 2019 |
| Targeting HIF1-alpha/miR-326/ITGA5 axis potentiates chemotherapy response in triple-negative breast cancer R Assidicky, UM Tokat, IO Tarman, O Saatci, PG Ersan, U Raza, H Ogul, ... Breast cancer research and treatment 193 (2), 331-348, 2022 | 22 | 2022 |
| Targeting adenosine with adenosine deaminase 2 to inhibit growth of solid tumors L Wang, LM Londono, J Cowell, O Saatci, M Aras, PG Ersan, S Serra, ... Cancer Research 81 (12), 3319-3332, 2021 | 21 | 2021 |
| TLR ligand loaded exosome mediated immunotherapy of established mammary Tumor in mice M Yildirim, TC Yildirim, N Turay, T Bildik, B Ibibik, I Evcili, PG Ersan, ... Immunology Letters 239, 32-41, 2021 | 16 | 2021 |
| The miR-644a/CTBP1/p53 axis suppresses drug resistance by simultaneous inhibition of cell survival and epithelial-mesenchymal transition in breast cancer. Oncotarget. 2016; 7 … U Raza, O Saatci, S Uhlmann, SA Ansari, E Eyüpoğlu, E Yurdusev, ... | 5 | |
| Toxic PARP trapping upon cAMP-induced DNA damage reinstates the efficacy of endocrine therapy and CDK4/6 inhibitors in treatment-refractory ER+ breast cancer O Saatci, M Cetin, M Uner, UM Tokat, I Chatzistamou, PG Ersan, ... Nature Communications 14 (1), 6997, 2023 | 1 | 2023 |
| EACR-MRS conference on seed and soil: in vivo models of metastasis I Teles Alves, N Cohen, PG Ersan, R Eyre, I Godet, D Holovanchuk, ... Clinical & Experimental Metastasis 34, 449-456, 2017 | 1 | 2017 |
| Abstract PO4-23-10: Restoring the efficacy of standard of care in treatment-refractory ER+ breast cancer by re-activation of cAMP-ROS-DNA damage axis O Saatci, M Cetin, M Uner, UM Tokat, I Chatzistamou, PG Ersan, ... Cancer Research 84 (9_Supplement), PO4-23-10-PO4-23-10, 2024 | | 2024 |
| Abstract A008: Toxic PARP trapping upon cAMP-induced DNA damage reinstates the efficacy of endocrine therapy and CDK4/6 inhibitors in treatment-refractory ER+ breast cancer O Saatci, M Cetin, M Uner, UM Tokat, I Chatzistamou, PG Ersan, ... Cancer Research 84 (1_Supplement), A008-A008, 2024 | | 2024 |
| Targeting LINC00152 activates cAMP/Ca2+/ferroptosis axis and overcomes tamoxifen resistance in ER+ breast cancer O Saatci, R Alam, KT Huynh-Dam, A Isik, M Uner, N Belder, PG Ersan, ... bioRxiv, 2023.11. 05.565697, 2023 | | 2023 |
| Overcoming tamoxifen resistance and inhibiting metastatic recurrence in estrogen receptor-positive breast cancer PG Ersan, O Saatci, O Tarman, R Mishra, N Belder, UM Tokat, ... Cancer Research 79 (13_Supplement), 2121-2121, 2019 | | 2019 |
| Thymidylate synthase maintains the de-differentiated state of aggressive breast cancers A Siddiqui, P Gollavilli, A Schwab, ME Vazakidou, PG Ersan, ... bioRxiv, 321943, 2018 | | 2018 |
| Identifying and targeting competing endogenous RNA (ceRNAs) networks to inhibit lung metastasis in triple negative breast cancer P Ersan, U Tokat, E Eyupoglu, U Raza, Y Riazalhosseini, C Alkan, ... Cancer Research 77 (13_Supplement), 2848-2848, 2017 | | 2017 |
| Competing endogenous RNA (ceRNAs) interaction network regulating lung metastasis in triple negative breast cancer PG Ersan, UM Tokat, E Eyupoglu, U Raza, Y Riazalhosseini, C Alkan, ... | | 2017 |
| TLR ligand loaded exosome mediated immunotherapy of established mammary Tumor in mice M Yıldırım, TC Yıldırım, N Turay, T Bildik, B İbibik, İ Evcili, PG Ersan, ... Elsevier BV, 0 | | |
| Targeting HIF1-alpha/miR-326/ITGA5 axis potentiates chemotherapy response in triple-negative breast cancer UM Tokat, IO Tarman, PG Ersan, U Raza, O Saatci, O Sahin, H Ogul, ... Springer New York LLC, 0 | | |
Ozgur SahinProfessor and Endowed Chair at Medical University of South CarolinaVerified email at musc.edu
